The pandemic brought unprecedented challenges for NHS. Especially as there wasn’t a pathway in place for COVID patients. Therefore, clinical teams had to develop agile ways of managing patients. For this, both patient and staff safety was the priority in workflows, along with streamlining processes. This was important in treating patients as swiftly and safely as possible. At the time, it wasn’t possible to electronically track COVID patients in the hospital. This was complicated by the need to isolate, which lead to some ward closures while others were dedicated to COVID patients. This was important in preventing cross-contamination.
In less than two weeks, Bleepa’s core workflows adapted to capture COVID-19 specific clinical information and treatment needs, like ventilation status. As well as providing all clinical-grade medical imaging. This followed intense consultation and agile product development. Bleepa was rolled out to be used to support clinicians with the COVID-19 pathway. In addition, Bleepa integrated with the Patient Administration System (PACS) to ensure accurate patient location.
Bleepa also developed features to support the electronic referral of COVID-19 patients to the respiratory inpatient and palliative care teams. And for research nurses who wanted to choose patients for the COVID-19 recovery trial. Bleepa also supported clinical communication with patient focused chat. In some cases, this stopped clinicians needing to see patients in person. Not only was this more efficient but also safer for staff by reducing unnecessary exposure to infected patients. Lastly, Bleepa made it possible to track patients as their condition improved or deteriorated and they moved around the hospital.
Through the intense collaboration with the team at the Royal Oldham Hospital, Bleepa became an even more powerful and relevant tool. It provides electronic patient referrals, remote access to clinical imaging, the ability to review cases and communicate with the rest of the clinical team. With remote patient referrals and reviewing, clinicians can reduce unnecessary contact with patients. Therefore, reduce their risk of infection. Bleepa also provided data that can be reviewed to find links between treatment and outcomes.
“It’s a testament to what can be delivered, in terms of a really great, viable product, when these sorts of teams get together, understand each other, have a really good working relationship and are able to develop something in collaboration. Now Bleepa is at a point where it speaks for itself.”
Dr Nevan Meghani
Respiratory Registrar